MedTrace Logo

Statin Therapy and COVID-19 Infection

NCT04407273 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 2159

Last updated 2021-03-11

No results posted yet for this study

Summary

Considering that simvastatin, and probably statins in general, interfere with SARS-cov-2 cellular uptake and some inflammatory pathways activated by the virus, those patients on statin therapy should be less vulnerable to infection and their clinical course and prognosis should be better than that in individuals not on statin therapy.

Conditions

Interventions

DRUG

observational

observational study

Sponsors & Collaborators

  • Institut Investigacio Sanitaria Pere Virgili

    lead OTHER

Principal Investigators

  • Lluís Masana, Dr · Institut Investigacio Sanitaria Pere Virgili

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-14
Primary Completion
2020-08-20
Completion
2020-12-30

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04407273 on ClinicalTrials.gov